Mid-Cap Biotech Companies Gaining Investor Attention
Mid-cap biotech companies are drawing renewed attention from institutional investors as capital markets recalibrate toward sustainable innovation rather than early-stage speculation. Positioned between emerging biotech startups and established pharmaceutical giants, mid-cap firms often combine clinical validation with scalable commercialization strategies. This balance increasingly makes them attractive in a biotech sector that has experienced both volatility … Read more
